Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher

Li F, Zeng Z, Xing S, Gullicksrud J, Shan Q, Choi J, et al. Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf. Nat Commun. 2018;9:5452 pubmed publisher

Cervera Carrascon V, Quixabeira D, Santos J, Havunen R, Zafar S, Hemminki O, et al. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncoimmunology. 2020;9:1761229 pubmed publisher

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, et al. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. Br J Cancer. 2018;118:1062-1073 pubmed publisher

Klann J, Remedios K, Kim S, Metz P, Lopez J, Mack L, et al. Talin Plays a Critical Role in the Maintenance of the Regulatory T Cell Pool. J Immunol. 2017;198:4639-4651 pubmed publisher

Yin S, Wang C, Yang N. Interleukin-4 enhances trafficking and functional activities of GM-CSF-stimulated mouse myeloid-derived dendritic cells at late differentiation stage. Exp Cell Res. 2011;317:2210-21 pubmed publisher